Prospective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy Trial
Tóm tắt
Micro-invasive glaucoma surgical implantation of trabecular micro-bypass stents, previously shown to be safe and effective for open-angle glaucoma (OAG) subjects during cataract surgery, was considered for evaluation as a sole procedure. The aim of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy after ab interno implantation of two Glaukos Trabecular Micro-Bypass iStent inject second generation devices in subjects with OAG. This study was performed at sites in France, Germany, Italy, Republic of Armenia, and Spain. In this pan-European, multi-center prospective, post-market, unmasked study, 99 patients with OAG on at least two topical ocular hypotensive medications who required additional IOP lowering to control glaucoma disease underwent implantation of two GTS400 stents in a stand-alone procedure. Patients were qualified if they presented with preoperative mean IOP between 22 and 38 mmHg after medication washout. Postoperatively, subjects were assessed at Day 1, Months 1, 3, 6, 7, 9, and 12. IOP, medication use and safety were assessed at each visit. Sixty-six percent of subjects achieved IOP ≤18 mmHg at 12 months without medication, and 81% of subjects achieved Month 12 IOP ≤ 18 mmHg with either a single medication or no medication. Mean baseline washout IOP values decreased by 10.2 mmHg or 39.7% from 26.3 (SD 3.5) mmHg to 15.7 (SD 3.7) mmHg at Month 12. Mean IOP at 12 months was 14.7 (SD 3.1) mmHg in subjects not using ocular hypotensive medications. Reduction from preoperative medication burden was achieved in 86.9% of patients, including 15.2% with reduction of one medication and 71.7% with reduction of two or more medications. Postoperative complications occurred at a low rate and resolved without persistent effects. In this series, implantation of two trabecular micro-bypass second generation stents in subjects with OAG resulted in IOP and medication reduction and favorable safety outcomes.
Tài liệu tham khảo
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51.
American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guidelines. Primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2010. Available at: http://www.aao.org/ppp. Last accessed January 6, 2014.
Samuelson TW, Katz LJ, Wells JM, Duh Y-J, Giamporcaro JE, for the US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459–67.
Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma. J Cataract Refract Surg. 2010;36:407–12.
Craven ER, Katz LJ, Wells JM, Giamporcaro JE, for the iStent Study Group. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up. J Cataract Refract Surg. 2012;38:1339–45.
Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783–801.
Johnstone MA, Grant WG. Pressure-dependent changes in structures of the aqueous outflow system of human and monkey eyes. Am J Ophthalmol. 1973;75:365–83.
Rosenquist R, Epstein D, Melamed S, et al. Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy. Curr Eye Res. 1989;8:1233–40.
Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96–104.
Arriola-Villalobos P, Martinez-de-la-Casa J, Fernandez-Perez J, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol. 2012;. doi:10.1136/bjophthalmol-2011-300218.
Spiegel D, Wetzel W, Neuhann T, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol. 2009;19:393–9.
Fea AM, Pignata, G, Bartoli E, et al. Prospective, randomized, double-masked trial of trabecular bypass stent and cataract surgery vs. cataract surgery alone in primary OAG: long-term data. Presented at the 2012 European Society of Cataract and Refractive Surgeons, Milan, Italy, September, 2012.
Bahler C, Hann C, Fjield T, et al. Second-generation trabecular meshwork bypass stent (iStent inject) increases outflow facility in cultured human anterior segments. Am J Ophthal. 2012;153:1206–13.
Bahler C, Smedley G, Zhou J, Johnson D. Trabecular bypass stents decrease intraocular pressure in cultured human anterior segments. Am J Ophthal. 2004;138:988–94.
Early Treatment Diabetic Retinopathy Study. Manual of operations. Chap. 12, 1985.
Arriola-Villalobos P, Martinez de la Casa JM, Diaz-Valle D, et al. Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataract. Br J Ophthalmol. 2013;97:1250–5.
Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. J Cataract Refract Surg. 2012;38:1911–7.
Katz LJ, on behalf of the MIGS Study Group. IOP and medication reduction after micro invasive glaucoma surgery with two trabecular micro-bypass stents in OAG. Presented at 2013 American Glaucoma Society Annual Meeting, San Francisco, CA, February, 2013.
Chang LJ, on behalf of the MIGS Study Group. Intraocular pressure reduction and safety outcomes after microinvasive glaucoma surgery with 2 trabecular bypass stents in OAG. Presented at 2013 American Society of Cataract and Refractive Surgeons Annual Meeting, San Francisco, CA, April, 2013.